Medicago is a clinical-stage biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs). Medicago’s VLP manufacturing technology is based on a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has the potential to offer speed and cost advantages over competitive technologies.